The three-year incidence of major hemorrhage among older adults initiating chronic dialysis

Manish M Sood1*, Sarah E Bota2,3, Eric McArthur2, Moira K Kapral2,4,5, Navdeep Tangri6, Greg Knoll1, Deborah Zimmerman1 and Amit X Garg2,3,7,8

Abstract

Background: For those who initiate chronic dialysis, knowing what proportion will experience 3-year outcomes of hemorrhage with hospitalization informs patient prognosis, disease impact, and the planning of trials and programs to prevent events.

Objectives: We examined the incidence of hemorrhage and related gastrointestinal endoscopic procedures in incident older dialysis patients and stratified patients by age, era, dialysis modality and whether recently prescribed anti-thrombotic medication.

Design: Retrospective cohort study

Setting: Ontario, Canada from 1998 to 2008 (n = 11,173)

Patients: All older patients (>65 years) who initiated chronic dialysis

Measurements: Hospitalization with hemorrhage and its subtypes (upper and lower gastrointestinal, intra-cerebral, subarachnoid) and related-gastrointestinal procedures.

Methods: Three-year outcomes of hospitalization with hemorrhage were expressed as cumulative incidence and incidence rate (number of events per 1,000 patient years). Results were stratified by patient age (66 to 74, 75 to 84, ≥ 85), era (1998 to 2001, 2002 to 2005, 2006 to 2008) and dialysis modality. Among those with hemorrhage, we examined prescriptions for anti-thrombotic medications (warfarin, clopidogrel) in the preceding 120 days.

Results: The 3-year cumulative incidence of hemorrhage was 14.4% (roughly 1 in 7 patients). By location, the 3-year cumulative incidence was 8.9% lower gastrointestinal, 6.1% upper gastrointestinal, 0.9% intra-cerebral and 0.1% subarachnoid hemorrhage. The 3-year cumulative incidence of gastrointestinal endoscopic procedures was 14.8%. The cumulative incidence and rate of hemorrhage were not appreciably different across the 3 age strata, by era or by dialysis modality. Among patients with a hemorrhage, 29.5% were prescribed warfarin in the preceding 120 days, and 8.4% clopidogrel.

Limitations: Recurrent events were not included.

Conclusions: Many older patients who initiate chronic dialysis will be hospitalized with hemorrhage and receive related procedures over the subsequent three years. Despite greater age and co-morbidity over the last decade this incidence has not changed.
Dialysis patients are known to experience a significant risk of hemorrhagic events. Accurate determination of the risk has been difficult due to variations in the definition of hemorrhage and the use of non-validated diagnostic codes in previous studies. Further it remains unclear if or to what magnitude the hemorrhagic risk changes with increasing age and over time.

What this adds
We found that one in seven patients (14.43%) will experience a hospitalization with a hemorrhage within the first three years of initiating dialysis and this high risk did not increase with age or improve over time.

Background
Patients who initiate chronic dialysis are older, have more co-morbid illness than a decade prior, and subsequently may experience more hospitalizations in follow-up. Hemorrhages are one of most common hospital admission diagnoses in the end-stage renal disease population and contribute significant morbidity and mortality [1]. Compared to the general population, the incidence of hemorrhage is considerably higher in those receiving dialysis with rates ranging from 35.4 to 80 per 1000-patient years (which is contingent on the study design, the definition used, method of outcome ascertainment and concurrent use of anti-thrombotic medications such as clopidogrel or warfarin) [2,3].

In the non-dialysis population, the incidence of hemorrhagic events has been declining over the last two decades, attributed to the widespread use of gastrointestinal endoscopic procedures, treatments for *H.pylori*-related ulcers and the use of proton pump inhibitors [4-8]. In an American dialysis population, the incidence of non-variceal upper gastrointestinal bleeding had not changed over the last decade despite increasing patient comorbidity [9,10]. It is unknown whether the same is true in other jurisdictions, or applies to other types of bleeding (lower gastrointestinal, intracranial bleeding) or related procedures (gastrointestinal endoscopy). Furthermore, the risk of bleeding appears to increase with advancing age [7]. In the non-CKD, non-dialysis population, hospitalizations for UGI hemorrhage per 100,000 population increased...
dramatically with age (<65 31.7, 66 to 75 197.4, > 75 425.2) with a similar trend observed for lower GI hemorrhage. As the average age of incident dialysis patients is increasing over time, it follows that there may a parallel rise in the risk of major hemorrhage [11]. Lastly, the hemorrhagic risk may differ based on the dialysis modality as patients on peritoneal and hemodialysis are well known to differ based on co-morbidities, exposures (to heparin with the hemodialysis procedure) and functional status.

In this study we examined older adults who initiated chronic dialysis in Ontario, Canada over a ten-year period to determine the 3-year cumulative incidence and incidence rate (per 1000 person years) of hemorrhage and related gastrointestinal endoscopic procedures. We further examined hemorrhage incidence across three age (66 to 74, 75 to 84, ≥85), era (1998 to 2001, 2002 to 2005, 2006 to 2008) and dialysis modality (peritoneal, hemodialysis) and considered whether patients with hemorrhagic events were recently prescribed anti-thrombotic medication.

**Methods**

**Study design and setting**

We conducted a population-based study of all older adults who initiated chronic dialysis in Ontario, Canada between January 1, 1998 and December 31, 2008 using linked health care databases. Ontario has approximately 13 million residents, 14% of whom are 65 years of age or older [12]. Residents have universal access to hospital care and physician services and those 65 years of age or older have universal prescription drug coverage. All healthcare encounters are entered in administrative databases and are held in a linked, de-identified form at the Institute for Clinical Evaluative Sciences (ICES). We conducted this study according to a pre-specified protocol that was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). The reporting of this study followed guidelines for observational studies [13] (Additional file 1: Table S1). Regional ethics approval was obtained.

**Data sources**

We ascertained patient characteristics, drug use, covariate information, and outcome data using records from five linked databases. We identified patients initiating chronic dialysis in Ontario through the Canadian Organ Replacement Registry (CORR) [11]. CORR is a national dialysis registry with information collected from all dialysis facilities in Canada on incident chronic dialysis patients [14,15]. The recorded information includes dialysis modality and the type of vascular access. We obtained vital statistics from the Ontario Registered Persons Database which contains demographic information on all Ontario residents who have ever been issued a health card. We used the Ontario Drug Benefit Plan database to identify prescription drug use. This database contains highly accurate records of all outpatient prescriptions dispensed to patients aged 65 or older, with an error rate of less than 1% [16]. We identified diagnostic and procedural information on all hospitalizations from the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD). We obtained information from the Ontario Health Insurance Plan database, which includes health claims for inpatient and outpatient physician services. Previously, we have used these databases to research renal health outcomes and health services [17-19]. Whenever possible, we defined patient characteristics, dialysis characteristics and outcomes using database codes that have been proven reliable when compared with manual chart review (Additional file 1: Table S2).

**Patients**

We studied patients who initiated chronic dialysis therapy within our 10 year accrual period. CORR captures patients who require chronic dialysis therapy; their date of dialysis initiation served as the index date (also referred to as the cohort entry date). We excluded the following people from analysis: i) those without at least one year of eligibility for prescription drug coverage (age less than 66) to avoid incomplete medication records, ii) those with a prior history of kidney transplantation or prior chronic dialysis, to focus on incident end-stage renal disease treated with chronic dialysis and iii) those who initiated chronic dialysis during a hospital stay and died prior to hospital discharge.

Known demographics and co-morbid risk factors for hemorrhage were recorded including age, hypertension, prior major hemorrhage [20], diabetes, cardiovascular disease including prior myocardial infarction, and atrial fibrillation in the five years preceding dialysis initiation. Antithrombotic therapy (warfarin, clopidogrel) was captured in the 30 and 120 days preceding the hemorrhagic event. In Ontario, acetyl-salicylic acid (ASA) is often available without a prescription and thus would not be captured in the Ontario Drug Benefit Plan.

**Outcomes**

All individuals were followed for three years after the initiation of chronic dialysis for the outcomes of interest. The primary outcome was the first hospitalization with non-traumatic major hemorrhage, a composite outcome defined by any of the following: upper and lower gastrointestinal (GI) hemorrhage, intra-cerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). The secondary outcome was each specific subtype of hemorrhage and all gastrointestinal endoscopic procedures that occurred during the hospital stay.

The components of non-traumatic major hemorrhage were specifically selected based on prior validation studies.
and the severity of each event [21,22]. Previous studies have reported positive predictive values of 90–98% for each of the specific subtypes of hemorrhage we used as secondary outcomes [21,22]. Non-validated hemorrhages, such as those associated with vascular access, and non-severe hemorrhages (e.g. epistaxis) were excluded. Gastrointestinal endoscopic procedures included gastroscopy, colonoscopy, sigmoidoscopy, duodenoscopy, & esophagoscopy. Hospitalizations for outcomes were identified using the International Classification for Disease (ICD), 9 and 10 codes (Additional file 1: Table S3).

Statistical analysis
The study period was categorized into three eras: 1998–2001, 2002–2005, 2006–2008, three age groups: 66–74, 75–84 and ≥85 years of age and dialysis modality (peritoneal dialysis and hemodialysis). Differences between baseline characteristics were evaluated using analysis of variance (ANOVA) and chi-squared tests. We determined frequencies and calculated a modified Charlson comorbidity index for all patients at baseline by era [23].

We calculated the three-year cumulative incidence of hemorrhagic events (defined as the proportion of patients who experienced the event at least once within the three-years of follow-up in percent) and three-year incidence rates (defined as the rate per 1,000 person-years of follow-up). For the primary outcome, patients were censored at the time of their first hemorrhagic event, death or end of follow-up period whereas for the secondary outcome of subtypes of hemorrhage or related-procedures, patients were censored only after the specific subtype of hemorrhage or related-procedure occurred, death or the end of the follow-up period. This allowed us to determine the specific subtype or related procedure incidence. Primary results were stratified by era (1998 to 2001, 2002 to 2005, and 2006 to 2008), age category (65–74, 75–84, ≥85) and dialysis modality. Trends were examined using the Cochrane-Armitage test. We examined whether patients with hemorrhage were prescribed anti-thrombotic medications (warfarin, clopidogrel) in the 30 days and 120 days preceding their hemorrhagic event. Of note, the three-year cumulative incidence does not account for time at risk, representing simply a proportion of events achieved with 3 years. In this regard, the incidence rate was also calculated.

Results
Our final study cohort included 11,173 incident chronic dialysis patients comprising 19,894.2 patient-years of follow-up with the average follow-up per person of 677 days (see cohort development Additional file 1: Figure S1). Baseline characteristics by era and age are presented in Table 1. Most patients were Caucasian (versus other races) and initiated hemodialysis (>80% of the cohort, versus peritoneal dialysis). A history of atrial fibrillation and hemorrhage were common in the older age groups. Patients who initiated dialysis in more recent years (versus earlier years) were slightly older and had greater comorbidity. Prescriptions at dialysis initiation for warfarin were unchanged (mean 12.2%, p = 0.098) whereas clopidogrel significantly increased from 0.5 to 8.0% (p < 0.001) in the more recent era compared to earlier. Among comorbidities prior to dialysis initiation, hemorrhage, acute coronary syndrome and the presence of a mechanical heart valve were more common in the recent era.

Three-year cumulative incidence and event rate of hemorrhage
The three-year cumulative incidence of hemorrhage was 14.43% with an event rate of 52.64 per 1000 person years (see Table 2). By site of bleeding, the cumulative incidence and event rates were highest for lower gastrointestinal (8.88% and 31.21 per 1000 person years) followed by upper gastrointestinal (6.06% and 20.94 per 1000 person years), intra-cerebral (0.85% and 2.85 per 1000 person years) and subarachnoid (0.10% and 0.33 per 1000 person years). The three-year cumulative incidence and event rate for the receipt of gastrointestinal endoscopy (upper, lower) was 14.86% and 54.45 per 1000 person years of patients. Patients with hemorrhage at more than one anatomical location occurred in 162 cases (1.45%).

Age and the three-year cumulative incidence and event rate of hemorrhage
The 3-year cumulative incidence and event rate for hemorrhage was similar across age groups (see Figure 1). They were highest in those 75–84 years of age (14.55%, 53.23 per 1000 person years) and lowest in those ≥85 years of age (13.95%, 50.78 per 1000 person years). Individuals ≥85 years of age had the highest 3-year cumulative incidence of lower gastrointestinal hemorrhage (9.30%, 32.85 per 1000 person years) and lowest incidence of upper gastrointestinal hemorrhage (5.04%, 17.3 per 1000 person years) and intra-cerebral hemorrhage (0.58%, 1.94 per 1000 person years). Individuals ≥85 years of age underwent substantially fewer gastrointestinal endoscopic procedures (9.59%, 34.14 per 1000 person years, p = 0.005) than those in the other 2 age categories.

Secular trends in the rates of hemorrhage
The 3-year cumulative incidence rates and event rates (per 1000 person years) of hemorrhage were consistent across time periods and varied from 14.15 to 14.36% and 51.57 to 52.29 (see Table 3). The highest 3-year cumulative incidence and event rate for lower gastrointestinal hemorrhage was seen in 2002–2005 (9.08%, 31.97 per 1000 patient-years). In the same era, the 3-year cumulative
### Table 1 Baseline characteristics of patients initiating chronic dialysis in Ontario, Canada from 1998 to 2008

| Characteristics                     | Total | Era of dialysis initiation | Patient age, years | p-value | 65-74 | 75-84 | ≥85 | p-value |
|-------------------------------------|-------|-----------------------------|--------------------|---------|-------|-------|-----|---------|
|                                     | n = 11,173 | n = 3,837 | n = 4,231 | n = 3,105 |       |       |     |         |
| **Era, year of dialysis initiation**|       | 1998-2001 | 2002-2005 | 2006-2008 |       |       |     |         |
| **Age, mean ± SD**                  | 75.8 ± 6.2 | 74.8 ± 5.8 | 76.1 ± 6.2 | 76.5 ± 6.43 | <0.001 |       |     |         |
| **Women,%**                         | 42.3 | 42.3 | 42.0 | 42.6 | 0.873 | 41.6 | 42.5 | 44.2 | 0.286 |
| **Race,%**                          |       |       |       |       |       |       |     |         |
| Caucasian                           | 77.0 | 70.0 | 80.7 | 80.7 | <0.001 | 73.9 | 79.4 | 80.5 | <0.001 |
| East Asian                          | 6.2 | 6.6 | 6.1 | 5.8 | 5.9 | 6.2 | 7.6 | 0.4 | 0.7 |
| South Asian                         | 3.0 | 2.6 | 3.1 | 3.5 | 4.1 | 2.4 | 0.7 | 0.6 | 0.4 |
| Aboriginal                          | 1.1 | 1.1 | 1.0 | 1.2 | 1.7 | 0.6 | 0.4 | 0.3 | 0.2 |
| Other                               | 4.9 | 4.4 | 5.1 | 5.1 | 6.2 | 3.8 | 3.5 | 1.8 | 0.9 |
| **Modality,%**                      |       |       |       |       |       |       |     |         |
| Hemodialysis                        | 81.4 | 78.5 | 82.3 | 80.4 | <0.001 | 77.6 | 82.8 | 83.4 | <0.001 |
| Peritoneal dialysis                 | 19.5 | 21.5 | 17.7 | 19.6 |        | 22.4 | 17.2 | 16.6 |        |
| **Medication*,%**                   |       |       |       |       |       |       |     |         |
| Clopidogrel                         | 4.5 | 0.5 | 5.6 | 8.0 | <0.001 | 4.3 | 4.7 | 4.8 | 0.571 |
| Warfarin                            | 12.2 | 11.8 | 11.9 | 13.3 | 0.098 | 10.6 | 13.5 | 13.9 | <0.001 |
| **Co-morbidity,%**                  |       |       |       |       |       |       |     |         |
| Atrial fibrillation                 | 14.7 | 14.0 | 15.3 | 14.9 | 0.258 | 12.2 | 16.6 | 17.8 | <0.001 |
| Stroke                              | 5.0 | 5.8 | 5.0 | 4.0 | 0.003 | 5.2 | 4.9 | 4.5 | 0.514 |
| Prior Major hemorrhage              | 10.1 | 8.9 | 10.1 | 11.7 | <0.001 | 10.0 | 9.8 | 12.4 | 0.039 |
| Acute coronary syndrome             | 13.6 | 12.7 | 14.7 | 13.2 | 0.026 | 1.8 | 2.1 | 1.8 | 0.588 |
| Deep vein thrombosis & pulmonary embolism | 1.9 | 1.8 | 1.8 | 2.3 | 0.202 | 1.8 | 2.1 | 1.8 | 0.588 |
| Mechanical heart valve              | 1.3 | 0.9 | 1.4 | 1.5 | 0.022 | 1.5 | 1.2 | 0.3 | 0.009 |
| **Modified Charlson Co-morbidity Index‡,%** |       |       |       |       |       |       |     |         |
| 2                                   | 27.4 | 27.7 | 26.7 | 28.0 | <0.001 | 26.8 | 27.5 | 30.2 | <0.001 |
| 3                                   | 13.9 | 17.5 | 12.9 | 10.9 |        | 12.2 | 14.7 | 18.2 |        |
| 4                                   | 19.0 | 20.1 | 17.3 | 19.9 |        | 18.6 | 19.0 | 20.9 |        |
| ≥5                                  | 39.7 | 34.7 | 43.0 | 41.2 |        | 42.4 | 38.8 | 30.6 |        |

*Medication was based on evidence of medication prescription at dialysis initiation.

‡We used a modified Charlson Index that gave each individual on dialysis an automatic two-points for moderate-to-severe kidney disease.

### Table 2 3-year cumulative incidence and incidence rates per 1,000 person year of total hemorrhages and hemorrhage subtypes

| Total hemorrhage | Lower gastrointestinal hemorrhage | Upper gastrointestinal hemorrhage | Intra-cerebral hemorrhage | Subarachnoid hemorrhage | Gastrointestinal endoscopy |
|------------------|-----------------------------------|-----------------------------------|--------------------------|-------------------------|---------------------------|
| N = 11,173       | 1612                              | 992                               | 677                      | 95                      | 11                        | 1660                      |
| 3-year cumulative incidence (%) | 14.43 | 8.88 | 6.06 | 0.85 | 0.10 | 14.86 |
| Event rate (per 1000 patient-years) | 52.64 | 31.21 | 20.94 | 2.85 | 0.33 | 54.45 |

1Counted as the first major hemorrhage at any anatomical location.

2Counted as the first hemorrhage at this anatomical location.

3Gastrointestinal endoscopy included gastroscopy, colonoscopy, sigmoidoscopy, duodenoscopy & esophagoscopy, when the procedure occurred during hospital stay.
incidence and event rate for upper gastrointestinal hemorrhage was lowest (5.91%, 20.41 per 1000 patient-years). The 3-year cumulative incidence of gastrointestinal endoscopic procedures ranged from 15.66 to 14.94% and was steady over time (p = 0.34). Intra-cerebral hemorrhages increased from 0.70 to 0.97%, p = 0.23 whereas the 3 year cumulative incidence of subarachnoid hemorrhage was relatively low.

Dialysis modality and three-year cumulative incidence and event rate of hemorrhage

The three-year cumulative incidence and event rate for total hemorrhage and its subtypes were all lower among peritoneal dialysis patients compared to hemodialysis however the differences were not statistically significant (see Table 4). Patients on peritoneal dialysis did undergo more gastrointestinal endoscopic procedures than patients on hemodialysis (17.84 vs. 14.13%, p < 0.0001).

3-year cumulative incidence and secular trends of hemorrhage and preceding prescription for anti-thrombotic medications

Among the 1,612 patients with hemorrhages, 4.20 and 8.37 were prescribed clopidogrel in the preceding 30 and 120 days (Table 5). Warfarin prescriptions occurred in

Table 3 Secular trends of the 3-year cumulative incidence (%) and event rates of hemorrhage (per 1000 person years), its subtypes, related endoscopy and all-cause mortality

| Outcome                      | Total | 1998-2001 | 2002-2005 | 2006-2008 | P value |
|------------------------------|-------|-----------|-----------|-----------|---------|
| Total hemorrhage             |       |           |           |           |         |
| 3-yr incidence               | 14.43 | 14.15     | 14.72     | 14.36     | 0.78    |
| Event rate                   | 52.64 | 51.57     | 53.87     | 52.29     |         |
| Upper gastrointestinal       |       |           |           |           |         |
| 3-yr incidence               | 6.06  | 6.12      | 5.91      | 6.18      | 0.05    |
| Event rate                   | 20.94 | 21.19     | 20.41     | 21.23     |         |
| Lower gastrointestinal       |       |           |           |           |         |
| 3-yr incidence               | 8.88  | 8.84      | 9.08      | 8.66      | 0.83    |
| Event rate                   | 31.21 | 31.01     | 31.97     | 30.42     |         |
| Intra-cerebral               |       |           |           |           |         |
| 3-yr incidence               | 0.85  | 0.70      | 0.90      | 0.97      | 0.23    |
| Event rate                   | 2.85  | 2.35      | 3.01      | 3.24      |         |
| Subarachnoid                 |       |           |           |           |         |
| 3-yr incidence               | 0.10  | 0.05      | 0.14      | 0.10      | 0.51    |
| Event rate                   | 0.33  | 0.17      | 0.47      | 0.32      |         |
| Gastrointestinal endoscopy   |       |           |           |           |         |
| 3-yr incidence               | 14.86 | 15.66     | 14.06     | 14.94     | 0.34    |
| Event rate                   | 54.45 | 57.76     | 51.36     | 54.61     |         |
16.6 and 29.53% in the preceding 30 and 120 days. Just over half the hemorrhagic events observed occurred within 30 days of prescription of either drug. Clopidogrel prescription prior to major bleeding increased over time from 1998–2001 to 2006–2008 (p < 0.001) and during the same time period, warfarin prescription declined 120 days prior to the event (p = 0.023). Co-prescription of both warfarin and clopidogrel in the period prior to a hemorrhage was relatively rare with a non-significant increase over time from 0.7% to 3.4% (p = 0.07).

Discussion
In this population-level study of older incident dialysis patients in Ontario, Canada, the 3-year cumulative incidence of hospitalization with hemorrhage was 14.43% or one in seven patients. The most common site of bleeding was lower gastrointestinal followed by upper gastrointestinal, intra-cerebral and subarachnoid hemorrhage, and many patients received an endoscopic procedure during their hospital admission. The incidence of hemorrhage was stable across age groups, over time, by dialysis modality and elevated among those recently prescribed anti-thrombotic medications. Among incident dialysis patients, the burden of hemorrhage is high and population-specific interventions are warranted.

Our finding of a high incidence of hemorrhage among incident dialysis patients with an observed rate of 52.64 per 1,000 person years is consistent with previous studies [2,3,24]. In prior large dialysis cohort studies event rates have ranged from 35.4 to 80 per 1,000 person-years [2,3]. Differences in the reported rates are attributable to variations in the definition of hemorrhage and inclusion criteria of individual studies. Olsen et al. examined hemorrhage requiring hospitalization in patients with atrial fibrillation and included urinary tract and airway hemorrhage [3]. Sood et al. reported an event rate of 80/1000 patient-years for hemorrhage with hospitalization with a broader definition including epistaxis, vascular access-related hemorrhage and subdural hematoma, and the study cohort included both incident and prevalent dialysis patients [2]. Of note the Canadian dialysis population may differ from international counterparts with relatively higher use of central venous catheters and warfarin all of which may impact the risk of hemorrhage [2,11].

As our rate estimates were determined in incident dialysis patients, they could serve to inform patients of their risk prior to dialysis initiation. The ability to quantitate

Table 4 Total 3-year cumulative incidence and event rates of hemorrhage (per 1,000 person years), its subtypes, and related endoscopy stratified by dialysis modality

| Outcome                  | Total 3-yr incidence | Event rate | P value |
|--------------------------|----------------------|------------|---------|
| Total hemorrhage         |                      |            |         |
| Hemodialysis             | 14.63%               | 53.37%     | 0.21    |
| Peritoneal dialysis      | 13.58%               | 48.86%     |         |
| Upper gastrointestinal   |                      |            |         |
| Hemodialysis             | 6.09%                | 21.07%     | 0.76    |
| Peritoneal dialysis      | 5.92%                | 20.38%     |         |
| Lower gastrointestinal   |                      |            |         |
| Hemodialysis             | 9.04%                | 31.85%     | 0.22    |
| Peritoneal dialysis      | 8.21%                | 28.59%     |         |
| Intra-cerebral           |                      |            |         |
| Hemodialysis             | 0.88%                | 2.94%      | 0.51    |
| Peritoneal dialysis      | 0.73%                | 2.45%      |         |
| Subarachnoid             |                      |            |         |
| Hemodialysis             | -                    | 0.30%      | <0.0001 |
| Peritoneal dialysis      | -                    | 0.46%      |         |
| Gastrointestinal endoscopy|                    |            |         |
| Hemodialysis             | 14.13%               | 51.64%     | <0.0001 |
| Peritoneal dialysis      | 17.84%               | 66.24%     |         |

Note: 3-year cumulative incidence of subarachnoid hemorrhage cell values were suppressed for the purposes of privacy and confidentiality.

Table 5 Secular trends of the proportion of patients who received an anti-thrombotic medication prescription 30 and 120 days preceding a hemorrhagic event

| Medication                     | Total | 1998-2001 | 2002-2005 | 2006-2008 | P value |
|--------------------------------|-------|-----------|-----------|-----------|---------|
| Clopidogrel (30 days)          | 4.2%  | 1.7%      | 4.3%      | 7.0%      | <0.0001 |
| Clopidogrel (120 days)         | 8.4%  | 2.6%      | 9.3%      | 14.1%     | <0.0001 |
| Warfarin (30 days)             | 16.6% | 17.5%     | 17.5%     | 14.3%     | 0.316   |
| Warfarin (120 days)            | 29.5% | 33.3%     | 29.2%     | 25.3%     | 0.023   |
| Warfarin + Clopidogrel (120 days) | 1.8% | 0.7%      | 1.6%      | 3.4%      | 0.072   |
risk of dialysis-related complications prior to dialysis initiation is increasingly important with the shift in demographics of the dialysis population to the elderly and need to balance quantity and quality of life. We further calculated the three-year cumulative incidence of hemorrhage as it may be a simple and meaningful way to communicate risk and understand disease burden from a patient perspective [25]. We found a 3-year cumulative incidence of 14.43% thus roughly 1 in 7 elderly dialysis patients will experience a hemorrhage requiring hospitalization within 3 years of dialysis initiation. This could be used in pre-dialysis discussions with patients to help them understand the risks of complications after dialysis initiation.

Among the specific subtypes of hemorrhagic events, we found upper and lower gastrointestinal hemorrhage (both well validated definitions of hemorrhage) to be the most common and roughly twenty to one hundred-fold higher in the elderly dialysis population compared to the general population [6,26,27]. Upper gastrointestinal hemorrhage has been previously reported in large US ESRD cohorts ranging from 23–57 per 1,000 person-years [10,28]. This is comparable to our rate of 20.94 per 1000 patient-years. Similarly, subarachnoid hemorrhage and intra-cerebral hemorrhage were found to occur at rates 3- to 10-fold higher in the dialysis population compared to those reported in the general population [29]. The rate of subarachnoid hemorrhage among those with ESRD was recently reported as 3-fold higher in the US compared to our study (0.74 vs. 0.33 per 1000-patient years) [29]. Differences among the rates may be attributable to a higher prevalence of associated risk factors (such as women US: 56.3% vs Canada: 42.3% and African Americans US: 25.7% vs Canada <5%) [29].

The risk of hemorrhage was stable over time, by age group and dialysis modality. The steady temporal trends have been reported in the US dialysis populations for upper gastrointestinal and subarachnoid hemorrhage, however, the comparable risk across age groups to our knowledge has not been previously reported [10,29]. The stable temporal trends in the dialysis population are in contrast to the general population where GI and SAH have been reported to be declining steadily over the last two decades [6,30]. This has been attributed to advances in prevention (acid suppressing medications) or related risk factors (hypertension treatment for subarachnoid hemorrhage) in the general population. Yet it remains unclear whether therapies are effective or treatment targets are similar or comparable in the dialysis population. The stable risk of hemorrhage with advancing age is reassuring and again provides important prognostic information for the elderly initiating dialysis. Of note, the absence of an increase in hemorrhagic events in the elderly may reflect a selection bias as elderly patients who are less likely to experience a hemorrhagic event may also be more apt to choose dialysis therapy over conservative treatments. Surprisingly despite similar hemorrhage rates, individuals ≥85 were much less likely to receive related endoscopic procedures (p = 0.005). Although the specific reasons for not performing endoscopic procedures were unknown, there is an increased risk of complications, often due to the bowel preparation or anesthetics, with advancing age and frailty [31]. The hemorrhagic risk appears to be similar based on dialysis modalities with the only difference detected being in gastrointestinal endoscopic procedures. It should be noted that the two cohorts are known to differ significantly in terms of demographics, co-morbidities, functionality and exposures [32]. These disparities were not accounted for in the present analysis and represent future areas on investigation.

A question of interest is the risk of hemorrhage with the use of anti-thrombotic medications [1,33-35]. We observed a large number of hemorrhagic events occurring following a recent warfarin or clopidogrel prescription. Of concern, the incidence of hemorrhage associated with clopidogrel prescription use was trending upward during the study period. To date, there remains very little evidence for efficacy of these medications in dialysis patients aside from warfarin use for a recent or recurrent thrombus [36,37]. Despite the increase in prescrptions for clopidogrel associated with hemorrhagic events over time, there was no significant increase in total hemorrhagic events. Whether this represents possible selection bias, increased use of co-interventions or declines in hemorrhagic events among patients not treated with anti-thrombotics remains unknown.

Our study has a number of strengths. Our definition of hemorrhage was stringent and limited to severe events requiring hospitalization. Previous studies included surrogate measures of bleeding (such as blood transfusion), bleeding events managed in the outpatient setting and subtypes with limited clinical impact (epistaxis) [2,3,24]. We used well validated definitions for our outcomes and excluded those lacking validation (vascular access related bleeding). We determined a three-year follow-up to ensure estimates of hemorrhage incidence would be useful for sample size calculations in future clinical trials. As CORR captures nearly all incident dialysis patients in Canada, our findings are representative and generalizable.

Our study has some limitations. We did not include traumatic or peri-operative bleeding events. Medication prescription was obtained only in cross section at the initiation of dialysis or 120 days preceding an event, and did not account for medication continuation and discontinuation over time. We lacked information on ASA use or INR control among warfarin users. We did not account for recurrent events or events in prevalent dialysis patients which would have considerably increased our
risk estimates. We did not have information regarding heparin-use during the hemodialysis procedure nor did we account for changes in modality over time.

Conclusion
Among incident dialysis patients are at high risk of hemorhagic events requiring hospitalization. These events are stable over time, across age groups and by dialysis modality. Further studies of risk stratification for these events, and strategies to reduce these events, are needed.

Additional file

Additional file 1: Table S1. STROBE Statement. Table S2. Coding definitions for demographic and co-morbid conditions. Table S3. Outcome Definitions. Figure S1. Patient selection.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors contributed to the study design and review of the manuscript. MMS and AG drafted the first version of the manuscript. EM conducted the data analysis. All authors read and approved the final manuscript.

Financial disclosures
Dr. Sood has served on advisory boards for Roche. Dr. Garg received an investigator-initiated grant from Astellas and Roche for a Canadian Institutes of Health Research study in living kidney donors and his institution received unrestricted research funding unrelated to this project from Pfizer.

Funding/Support
This study was supported by the Institute for Clinical Evaluative Sciences (ICES) Western Site. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). ICES Western is funded by an operating grant from the Academic Medical Organization of Southwestern Ontario (AMOSO). This project was conducted with members of the provincial ICES Kidney, Dialysis, and Transplantation Research Program, which receives programmatic grant funding from the Canadian Institutes of Health Research. The opinions, results and conclusions are those of the authors and are independent from the funding sources. No endorsement by ICES, Research. The opinions, results and conclusions are those of the authors and receives programmatic grant funding from the Canadian Institutes of Health Research.

Role of the sponsor
The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding sources.

Author details
1 Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa Institute for Clinical Evaluative Sciences, Civic campus, 2-014 Administrative Services Building, 1053 Carling Avenue, Box 693, Ottawa, ON, Canada. 2 Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 3 Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. 4 Department of Medicine, University of Toronto, Toronto, ON, Canada. 5 The Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada. 6 Seven Oaks General Hospital, Winnipeg, MB, Ontario, Canada. 7 Kidney Clinical Research Unit, Division of Nephrology, Western University, London, ON, Canada. Division of Nephrology, Department of Medicine, Western University, London, ON, Canada.

Received: 7 May 2014 Accepted: 8 August 2014 Published: 2 September 2014

References
1. Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest 2009, 136(4):1128–1133.
2. Sood MM, Larkins M, Thumma JR, Tentori F, Gillespie BW, Fukuhara S, Mendelssohn DC, Chan K, de Sequeira P, Komenda P, Rigatto C, Robinson BW. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 2013, 84(3):600–608.
3. Olesen JB, Lip GYH, Kamper A-L, Hommel K, Kaber L, Lane DA, Lindhardsen J, Gløersen GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012, 367(7):625–635.
4. Gomes T, Mandl D, Holtbrook AM, Paterson JM, Hellings C, Jaufler DN: Rates of hemorrhage during warfarin therapy for atrial fibrillation. Can Med Assoc J 2013, 185(2):E121–E127.
5. Ommen C, Imhof M, Ruppert C, Janzik U, Vogt C, Freiling T, Becker K, Neumann F, Faust S, Heller K, Haas K, Jurisch R, Wenzel EG, Normann S, Bachmann O, Delgadillo J, Seidel F, Franke C, Lüthen R, Yang Q, Reinhold C: Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005, 40(8):914–920.
6. van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol 2008, 22(2):209–224.
7. Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009, Ann J Gastroenterol 2012, 107(8):1190–1195.
8. Zuccaro G: Epidemiology of lower gastrointestinal bleeding, Best Pract Res Clin Gastroenterol 2008, 22(2):255–262.
9. Luo J-C, Leu H-B, Huang K-W, Huang C-C, Hou M-C, Lin H-C, Lee FY, Lee SD. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. Can Med Assoc J 2011, 183(18):E1345–E1351.
10. Levy A, O’Brien B, Sellors C, Grootendorst P, Willison D: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Pharmaco 2003, 100(2):67–71.
11. Garg AX, Meirambayeva A, Huang A, Kim J, Prasad GR, Knoll G, Boudwine N, Lok C, McFarlane P, Karpinski L, Storlesky L, Kralenbach S, Lam N, Thomas SM, Dipchand C, Reeve P, Doshi M, Gibeisy T, Bunt C, Young A: Cardiovascular disease in kidney donors: matched cohort study. BMJ 2012, 344:e1203.
12. Ritchie J, Chalmers K, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Mannino M, OliverMJ, Quinn RR, Suri RS, Wald R, Yan AT, Garg AX. Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dial Transplant 2012, 27(4):1591–1598.
13. Lam NN, Jain AK, Hackam DG, Cuerden MS, Suri RS, Huo CY, Li P, Clark WF, Garg AX: Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney Int 2009, 76(11):1172–1179.
14. Pisters R, Lane DA, Nieuwlaat R, van der Meiden CJ, Crins H, Lip GYH: A novel user-friendly score (hassbled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey. Chest 2010, 138(3):900–1100.
15. Arnason T, Wells PS, van Walraven C, Forster AJ: Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006, 118(2):253–262.
16. Kokotailo RA, Hill MD: Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10, Stroke 2005, 36(8):1776–1781.
23. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA: Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis 2003, 42(1):125–132.

24. Holden RM, Harman GJ, Wang M, Holland D, Day AG: Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008, 3(1):105–110.

25. Bonita R, Kjellstrom T: Basic Epidemiology. 2nd edition. Geneva: World Health Organization (WHO) Press; 2006.

26. Hernández-Díaz S, Rodríguez LAG: Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies. J Clin Epidemiol 2002, 55(2):157–163.

27. Feinman M, Haut ER: Upper gastrointestinal bleeding. Surg Clin North Am 2014, 94(1):43–53.

28. Haimanot Wasse DLG, Ball AM, Kestenbaum BR, Seliger SL, Donald S, Stehman-Breen CO: Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003, 64:1455–1461.

29. Sahuja A, Schold JD, Kumar G, Katzan I, Naveenethan SD: Nontraumatic subarachnoid hemorrhage in maintenance dialysis hospitalizations: trends and outcomes. Stroke 2014, 45(1):71–76.

30. Østbye T, Levy AR, Mayo NE: Hospitalization and case-fatality rates for subarachnoid hemorrhage in Canada from 1982 through 1991: the Canadian Collaborative Study Group of Stroke Hospitalizations. Stroke 1997, 28(4):793–798.

31. Razavi F, Gross S, Katz S: Endoscopy in the elderly: risks, benefits, and yield of common endoscopic procedures. Clin Geriatr Med 2014, 30(1):133–147.

32. Perl J, Wald R, McFarlane P, Bargman JM, Vonesh E, Na Y, Jassal SV, Mozt L: Hemodialysis vascular access modifies the association between dialysis modality and survival. J Am Soc Nephrol 2011, 22(6):1113–1121.

33. Sood MM, Komenda P, Tangri N: Anticoagulation in patients with kidney disease: one size does not fit all. Thromb Res 2013, 131(6):469–471.

34. Sood M, Tangri N: Atrial fibrillation and chronic kidney disease. N Engl J Med 2012, 367(22):2157–2159.

35. Sood MM, Rigatto C, Bueti J, Lang C, Miller L, Ponnampalam A, Reslerova M, Sood A, Komenda P: Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 2009, 24(10):3162–3167.

36. Hiremath S, Holden RM, Fergusson D, Zimmerman DL: Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009, 4(8):1347–1355.

37. Miller L, Sood M, Sood A, Reslerova M, Komenda P, Rigatto C, Bueti J: Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Int Urol Nephrol 2010, 42(4):1007–1014.

doi:10.1186/s40697-014-0021-x

Cite this article as: Sood et al: The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Canadian Journal of Kidney Health and Disease 2014 1:21.